German life sciences firm Bayer AG recently combined its pharmaceutical research and development activities in oncology, hematology, ophthalmology, gynecology, and cardiology into a new unit under the management of its pharmaceuticals division, the company announced Thursday.
“The combined research organization will enable us to seamlessly steer all of the important activities of Research and Development, with a single objective to further enhance the delivery of much needed new treatment options to patients,” Dieter Weinand, president of the German firm’s Pharmaceuticals division and member of Bayer AG’s Board of Management, said in a statement.
Bayer named Joerg Moeller, 53, the firm’s president head of Development within its Pharmaceuticals division, as the new leader of the unit. He will assume the new rule on Jan. 1. The head of the firm’s Drug Discovery unit, Andreas Busch, will depart Bayer for a role at another company.
“Joerg has an exceptional track record of bringing new medicines to patients, which have the potential to increase their quality of life and address serious medical conditions, and I trust that our team will be even more successful in doing so together under his leadership,” said Weinand.